Structure Therapeutics (NASDAQ:GPCR) Sets New 1-Year Low – Here’s Why

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $28.32 and last traded at $28.41, with a volume of 74570 shares traded. The stock had previously closed at $31.48.

Wall Street Analyst Weigh In

GPCR has been the subject of several research reports. HC Wainwright initiated coverage on shares of Structure Therapeutics in a research report on Wednesday, December 4th. They set a “buy” rating and a $80.00 price target for the company. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target on the stock. JMP Securities reissued a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $86.50.

Structure Therapeutics Price Performance

The firm has a fifty day moving average price of $35.95 and a two-hundred day moving average price of $39.17. The stock has a market capitalization of $1.62 billion, a PE ratio of -37.64 and a beta of -3.41.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Bank of Montreal Can acquired a new position in shares of Structure Therapeutics during the second quarter worth $1,064,000. Lighthouse Investment Partners LLC acquired a new position in shares of Structure Therapeutics during the second quarter valued at about $1,178,000. Vestal Point Capital LP raised its position in shares of Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after purchasing an additional 590,000 shares during the last quarter. abrdn plc boosted its stake in Structure Therapeutics by 132.7% in the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock worth $9,528,000 after purchasing an additional 123,789 shares in the last quarter. Finally, Pier Capital LLC grew its position in Structure Therapeutics by 32.7% during the 3rd quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock worth $5,894,000 after purchasing an additional 33,087 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.